Neogenomics (NEO) PT Raised to $19 at Morgan Stanley
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- Goldman data shows hedge funds cut leverage at fastest pace since March
Tweet
Share
E-mailGet Alerts NEO Hot Sheet
Price: $16.49 --0%
Rating Summary:
15 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 15 | New: 12
Rating Summary:
15 Buy, 6 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 15 | New: 12
Join SI Premium – FREE
Morgan Stanley analyst Tejas Savant raised the price target on Neogenomics (NASDAQ: NEO) to $19.00 (from $18.00) while maintaining a Equalweight rating.
You May Also Be Interested In
- Neogenomics (NEO) PT Raised to $24 at Piper Sandler
- EverQuote (EVER) PT Raised to $35 at Needham
- EVgo, Inc. (EVGO) PT Lowered to $2 at Cantor Fitzgerald
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
